retatrutide clinical trial safety data Lilly's triple agonist achieves 16.8% weight loss in phase 3 VisualAbstract: Retatrutide reduces body weight

Weeks 13-20 (6-8mg): entering the therapeutic range The 6mg and 8mg doses represent the therapeutic sweet spot for many people

It advised plastic surgeons to prepare for a growing patient population as demand for rejuvenation procedures rises alongside reports of GLP-1-related appearance changes

Theyre also testing newer and more powerful meds

The hazard ratio was 0.74, meaning roughly one-quarter fewer serious cardiac events in the semaglutide group

For appetite suppression and weight loss, the timeline differs somewhat

Cardiovascular side effects with semaglutide are generally mild, and the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in people with established heart disease